March-Common Cancers
Spotlight on Research in Breast, Ovarian, and Prostate Cancers
According to the American Cancer Society, a total of 408,110 people were diagnosed with breast (194,280), ovarian (21,550), and prostate (192,280) cancers in 2009. As the Baby Boomer generation ages, these diseases have the potential to become more prevalent.
Recognizing the impact that breast, ovarian, and prostate cancers have on the American population, Innovation.org highlights important research into these types of cancer. Click on the links below to read more about treatments and research.
Innovation in CancerClick here to learn about more than 861 medicines and vaccines in development that offer hope in the fight against cancer.
ResourcesMedicines in Development DatabaseClick here to access our medicines in development database, which contains information about drugs currently in clinical trials or at FDA for review across all diseases.
Clinical Trials ResourcesClick here to visit our new Clinical Trials Resources page to learn more about ongoing clinical trials for cancer and many other diseases in the United States and around the world.
Introduction to Breast CancerClick here to learn more about breast cancer, the second most common form of cancer among women after skin cancer, including specific treatments and progress in current research.
Patient PerspectivesToday there are treatments for breast, ovarian, and prostate cancers that greatly ease the burden for those living with the disease and increase survival rates.
Click here to read one patient’s story about living with breast cancer and learn how advances in treatments impact patient lives.
New Approvals
Researchers have made many advances in successfully developing treatments for breast, ovarian, and prostate cancers. Medical advances have allowed researchers to develop more effective, targeted treatments, with fewer side effects.
Click here for information about recent advances in the treatment of some of the most prevalent cancers.
Recent FDA Approvals
- Afinitor® - everolimus – approved 3/30/2009. For the treatment of advanced kidney cancer in patients whose cancer has progressed after other treatments.
- Treanda® – bendamustin hydrochloride – approved 3/20/2008. For treatment of chronic lymphocytic leukemia.
Featured Studies and Reports
As part of its ongoing effort to encourage new research and pharmaceutical innovation, Innovation.org highlights key studies and reports into critical disease areas. Read about recent research in common cancers in the reports below.
Click here to view more featured studies & reports.
Newsletters
Innovation.org publishes newsletters that highlight new and innovative research in many disease areas, including cancer. Click on the links below to view past newsletters spotlighting cancer research.
Click here to view the current issue of the Innovation.org newsletter.
Charts
The following charts demonstrate the important role of new medicines in improving life for patients with common cancers.
Click here to view all of the charts listed on Innovation.org.
Innovation in Breast, Ovarian, and Prostate Cancers – Discoverers Awards
Each year, PhRMA honors pharmaceutical research scientists whose research and development of new medicines have greatly benefited humankind, and whose dedication and interest in improving the quality of life exemplify the best in the research industry with the Discoverers Award.
The 1998 Discoverers Award went to Gareth J. Sanger, Ph.D., and Michael B. Tyers, Ph.D., for their contributions to the discovery of Zofran®, Kytril®, and Imitrex®, three drugs that hat have changed the course of cancer therapy. The drugs they discovered treat emesis, the severe vomiting and nausea that follow administration of powerful anti-cancer drugs. These powerful anti-cancer treatments are often used to treat breast, ovarian, and prostate cancers.
Click here for a list of all of the Discoverers Awards since 1987.
back to top
